DIESSE Biotech Campus - Inauguration today of the most advanced Italy based and European excellence IVD biotechnology centre

Monteriggioni, 5th September 2023 - Today, in Monteriggioni, DIESSE Biotech Campus has been officially inaugurated. It is the largest Research&Development and Biotechnology Production Centre in Italy dedicated to In Vitro Diagnostic Devices (IVD) and among the most important and advanced in Europe. The DBC is the first production site in this filed under the concept of Industry 5.0, based on lean manufacturing, white economy and sustainability.

With an investment of over 25 millions euro, the new campus has been built in two years by DIESSE Diagnostica Senese Spa Società Benefit. Backed by ARCHIMED investment fund, DIESSE is present in more than 100 countries worldwide with solutions dedicated to the monitoring of immune system status by means of serological assays and automatic measurements of the erythrocyte sedimentation rate (ESR).

The inauguration ceremony, held today, was attended by key figures and institutions. It has been not only the celebration of DIESSE's solid innovative achievement, but also an important occasion to discuss the matters related to the dynamics of Industry 5.0 development.

After the introductory speech from Massimiliano Boggetti, CEO of DIESSE, Prof. Giovanni Stea from the Department of Computer Engineering at the University of Pisa highlighted the fundamental principles of Industry 5.0, the new industrial revolution.

The ceremony was concluded by a round table moderated by the journalist Virginia Masoni and titled "Industry 5.0: A Boost for the Italian Economy or a Restraint to Industry Competitiveness?". Notable personalities took part to the meeting, such as Eugenio Giani, President of the Tuscany Region; Maurizio Marchesini, Vice-President of Industry and Medium-sized Companies for Confindustria; Achille Iachino, General Director for Medical Devices and Pharmaceutical Services for the Ministry of Health; Leonardo Marras, Assessor of Economics for the Tuscany Region; Fabio Seggiani, Secretary General of CGIL Siena; Riccardo Pucci, Secretary General of CISL Siena; as well as messages from Adolfo Urso, Minister for Industry and Made in Italy and Marcella Panucci, Head of Cabinet of the Ministry for Universities and Research.

"The adoption of the Industry 5.0 approach in creating the campus is fully in line with DIESSE's "human centric" vision, fostered in the company and in its diagnostic solutions. It represents our concrete dedication to the cornerstone values of the company - People, Planet, and Prosperity. These are the fundamental principles which lead our company to offer innovative solutions for immune system diagnostics," states Massimiliano Boggetti.

With an area of 10,000m sq, DIESSE Biotech Campus incorporates Italian design and cutting-edge technology with automated production of diagnostic tests, analytical instruments and softwares to create complete solutions for IVD laboratories. By investing over 10% of its profits on R&D, DIESSE proves its continuous dedication to innovation and progress.

The biotechnological research center for tests, instruments and software stands out as one of the unique features of the DBC. With its 1000 sqm, the BSL3 area for the production of bacterial, viral, and recombinant biomaterials featuring an automated Class III biobank and serving the manufacturing plant, is the core of the technologies produced by the company. The biobank makes it possible to store viruses, bacteria and recombinant cells up to biosafety level 3 and represents a significant contribution to biomedical research and innovation. The campus's short chain supply is completed by eco-friendly plastics moulding, chemistry and filling & packaging departments.

The center features reduced ecological impact and is totally self-sufficient in terms of energy. The installation of a solar powered system of 600kW, CO2 emission monitoring, a deep well water supply, and a waste minimization strategy represent innovative solutions to reduce our impact on the environment. The DBC was built using as many recyclable materials as possible, to adhere to sustainability principles. DIESSE is therefore classified as a Benefit Company striving to integrate environmental and social objectives, focusing to combine profit with equity and sustainability, which in our opinion is a fundamental goal for anyone working in the medical field.

With over 200 people, the campus is a highly qualified job opportunity, contributing to the dynamism of the surrounding work environment.

The inauguration of the DIESSE Biotech Campus is an important step forward in the scenario of research and innovation in Italy, granting significant benefits both in terms of economic development and progress for human health and the environment.